JP2004285076A5 - - Google Patents

Download PDF

Info

Publication number
JP2004285076A5
JP2004285076A5 JP2004155357A JP2004155357A JP2004285076A5 JP 2004285076 A5 JP2004285076 A5 JP 2004285076A5 JP 2004155357 A JP2004155357 A JP 2004155357A JP 2004155357 A JP2004155357 A JP 2004155357A JP 2004285076 A5 JP2004285076 A5 JP 2004285076A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004155357A
Other languages
Japanese (ja)
Other versions
JP2004285076A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2004285076A publication Critical patent/JP2004285076A/ja
Publication of JP2004285076A5 publication Critical patent/JP2004285076A5/ja
Withdrawn legal-status Critical Current

Links

JP2004155357A 1992-06-09 2004-05-25 M−csfの結晶化 Withdrawn JP2004285076A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89651292A 1992-06-09 1992-06-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP6501713A Division JPH08507916A (ja) 1992-06-09 1993-06-09 M−csfの結晶化

Publications (2)

Publication Number Publication Date
JP2004285076A JP2004285076A (ja) 2004-10-14
JP2004285076A5 true JP2004285076A5 (enExample) 2005-08-11

Family

ID=25406334

Family Applications (2)

Application Number Title Priority Date Filing Date
JP6501713A Withdrawn JPH08507916A (ja) 1992-06-09 1993-06-09 M−csfの結晶化
JP2004155357A Withdrawn JP2004285076A (ja) 1992-06-09 2004-05-25 M−csfの結晶化

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP6501713A Withdrawn JPH08507916A (ja) 1992-06-09 1993-06-09 M−csfの結晶化

Country Status (7)

Country Link
US (2) US5866114A (enExample)
EP (2) EP0955365A3 (enExample)
JP (2) JPH08507916A (enExample)
AT (1) ATE195553T1 (enExample)
CA (1) CA2137793C (enExample)
DE (1) DE69329247T2 (enExample)
WO (1) WO1993025687A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
CA2249007A1 (en) * 1996-03-14 1997-09-18 Takeshi Shibuya Parasite-derived anti-inflammatory immunomodulatory protein
WO2001034177A2 (en) * 1999-11-08 2001-05-17 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health Method of treating a viral infection using antagonists of macrophage colony stimulating factor
CN100439397C (zh) 2001-02-09 2008-12-03 基因技术股份有限公司 Igf-1的结晶
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
ATE468862T1 (de) 2001-07-11 2010-06-15 Maxygen Inc G-csf konjugate
US7563595B2 (en) * 2002-11-08 2009-07-21 University Of South Florida Nucleic acids encoding functional splice variants of the α7 nicotinic acetylcholine receptor subunit and methods for producing the encoded proteins
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2005057169A2 (en) * 2003-12-05 2005-06-23 Trellis Bioscience, Inc. Homogeneous competition assays
WO2005070447A2 (en) * 2004-01-21 2005-08-04 Chiron Corporation M-csf muteins and uses thereof
US20060094081A1 (en) * 2004-10-22 2006-05-04 Carsten Schubert Crystal structure of the c-fms kinase domain: applications and use of heterologous substitutions of kinase insert domains for crystallization
US7381805B2 (en) 2005-06-01 2008-06-03 Maxygen Holdings, Ltd. Compositions comprising mixtures of positional PEG isomers of PEGylated G-CSF
KR100970770B1 (ko) 2008-02-12 2010-07-16 한국기초과학지원연구원 결정성 재조합 단백질 휴먼 에스피오티 및 이의 결정화방법
US8183207B2 (en) * 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
US8080246B2 (en) * 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
AR075899A1 (es) * 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP2949670B1 (en) 2009-12-10 2019-02-27 F. Hoffmann-La Roche AG Antibodies binding preferentially human csf1r extracellular domain 4 and their use
KR101656548B1 (ko) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 csf-1r에 대한 항체 및 이의 용도
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトcsf−1rに対する抗体及びその使用
SMT201900074T1 (it) 2010-05-04 2019-02-28 Five Prime Therapeutics Inc Anticorpi che legano csf1r
US20140378537A1 (en) 2011-09-09 2014-12-25 Genentech, Inc. Treatment of th17 mediated inflammatory diseases
EP2791174B1 (en) 2011-12-15 2018-02-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN104684582A (zh) 2012-08-31 2015-06-03 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
CN113350501A (zh) 2014-06-23 2021-09-07 戊瑞治疗有限公司 用结合集落刺激因子1受体(csf1r)的抗体治疗病状的方法
AU2015339306B2 (en) 2014-10-29 2021-07-22 Bristol-Myers Squibb Company Combination therapy for cancer
EA201791421A1 (ru) 2014-12-22 2017-10-31 Файв Прайм Терапьютикс, Инк. Антитела против csf1r для лечения pvns
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗csf-1r抗体の間欠投与
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 抗pd-l1/pd1治療の不成功後の、抗pd-l1抗体との組み合わせでの抗csf-1r抗体を用いた腫瘍の治療
CN106843149A (zh) * 2017-03-28 2017-06-13 吴小江 一种机械零固件产品加工系统
CA3073531A1 (en) 2017-09-13 2019-03-21 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4672108A (en) * 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPS62106000A (ja) * 1985-10-30 1987-05-16 Fujitsu Ltd 生体高分子結晶自動作製装置
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) * 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5032676A (en) 1986-10-14 1991-07-16 Immunex Corporation Nonglycosylated analogs of human colony stimulating factors
WO1988003173A2 (en) * 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
ATE111921T1 (de) * 1988-06-03 1994-10-15 Chugai Pharmaceutical Co Ltd Menschlicher kristallinischer granulocyt- koloniestimulierungsfaktor und dessen herstellung.
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
IE66494B1 (en) * 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
JP2975109B2 (ja) * 1989-12-21 1999-11-10 ノボ ノルディスク アクティーゼルスカブ 酵素の結晶化方法
DE69231467T2 (de) * 1991-05-10 2001-01-25 Genentech, Inc. Auswählen von agonisten und antagonisten von liganden

Similar Documents

Publication Publication Date Title
BE2020C513I2 (enExample)
JP2005152658A5 (enExample)
BE2014C002I2 (enExample)
JP2005011489A5 (enExample)
GB2431057A8 (enExample)
JP2004249116A5 (enExample)
AT500847B8 (enExample)
CN300764069S (zh) 便携式媒体播放机
CN300894877S (zh) 服装(南航空姐立领连衣裙)
CN301030000S (zh) 液体分配阀入口
CN301001068S (zh) 椅子
CN3364427S (enExample)
CN3357732S (enExample)
CN3356637S (enExample)
CN3373426S (enExample)
CN3355806S (enExample)
CN3368136S (enExample)
CN3384646S (enExample)
CN3385196S (enExample)
CN3376032S (enExample)
CN3381870S (enExample)
CN3357406S (enExample)
CN3371307S (enExample)
CN3372875S (enExample)
CN3366641S (enExample)